Otsuka Pharmaceutical Company, Limited

Motohiro Itotani

Makoto Matsumoto

Yoshikazu Haraguchi

Isao Takemura

Hiroshi Shimizu

Hirofumi Sasaki

Shin Miyamura

Hidetsugu Tsubouchi

Kuninori Tai

Takeshi Kuroda

Hideaki Kuroda

Yohji Sakurai

Takumi Sumida

Tae Fukushima

Norimitsu Hariguchi

Masanori Kawasaki

Takeshi Hasegawa

Hiroshi Yamashita

Seiji Sato

Nobuaki Ito

Kazumi Kondo

Tatsuyoshi Tanaka

Kunio Oshima

Satoshi Shimizu

Yasuhiro Menjo

Shinichi Taira

Takashi Okamoto

Shigekazu Fujita

Takayuki Matsuzaki

Yohei Hayashi

Haruka Takahashi

Noriaki Takemura

Jun Matsubara

Yasuo Koga

Makoto Komatsu

Hokuto Yamabe

Masataka Ueda

Yoshikazu Kawano

Shuuji Matsumura

Hiroyuki Hashizume

Yukitaka Uematsu

Toshio Shinohara

Shunpei Ishikawa

Tatsuo Tomishige

Yuya Nakai

Kinue Ohguro

Satoshi Matsuda

Takashi Oshiyama

Toshiyuki Onogawa

Kenji Tsujimae

Atsunori Kaneshige

Miki Matsuba

Sunao Nakayama

Naohide Kanemoto

Hiromi Yata

Kazuho Kohashi

Mikayo Hayashi

Izuru Nakamura

Xiuhao Chen

Naohiro Isono

Tsuyoshi Nagase

Chiharu Matsumura

Kazuho Tanaka

Yuji Seike

Hiroyuki; Daiaparesu 1401 Hashizume

Takeshi; Daiichiaijitsuhaitsu 607 Hasegawa

Shin; 147-13 Mukaininokoshi Miyamura

This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

Cyanotriazole compounds

It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.

Heterobicyclic compounds and their use for the treatment of tuberculosis

The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof,

6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides

The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and &#x2014;(CH2)nR2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against, multi-drug-resistant, and atypical acid-fast bacteria. 

2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis

A heterocyclic compound or a salt thereof represented by the formula (1): where Rrepresents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and Rrepresents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. 

Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders

The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein Rrepresents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, Rrepresents a group &#x2014;ORor the like, and Rrepresents a hydrogen atom, C1-C6 alkyl group or the like, or Rand &#x2014;(CH)Rmay bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein Ris hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against, multi-drug-resistant, and atypical acid-fast bacteria.

2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles

Growing community of inventors

Tokushima, Japan

Motohiro Itotani